UK and US Reciprocal Drug Approvals Could Be on the Horizon

Marks & Clerk, an intellectual property firm based in London, says that reciprocal drug approvals between the UK and US may be on the horizon, potentially as early as 2024. The firm gleaned this information from a recent UK Medicines and Healt­care products Regulatory Agency (MHRA) guidance about international collaborations post-Brexit.

According to Paul Schloesser, “How that would come about is after the UK’s “Reliance Procedure” — a way to ensure patients in Great Britain post-Brexit could still access new medicines — expires. The procedure, in short, allows MHRA to utilize positive EC decisions to fast-track the approval process for marketing authorizations in Great Britain. Back in September, the agency announced that the procedure would be extended through the end of 2023.”

To read more, click here.

(Source: Endpoints News, February 16^th, 2023)